Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

NCT06624475 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Basal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Relatlimab plus Nivolumab

Sponsor

University of California, San Diego

Collaborators

[object Object]